Jensen N O, Dupont E, Hansen E, Mikkelsen B, Mikkelsen B O
Department of Neurology, University Hospital of Hvidovre, Denmark.
Acta Neurol Scand. 1988 May;77(5):422-5. doi: 10.1111/j.1600-0404.1988.tb05930.x.
Flucuations in motor performance is a major problem in long-term levodopa treatment of Parkinsonian patients. A slow release preparation of levodopa with benserazide, Madopar HBS, has been developed in an attempt to decrease this problem. Eleven of 22 Parkinsonian patients with advanced disease and marked fluctuations experienced long-lasting benefit with reduction of their fluctuations in motor performance on treatment with Madopar HBS; 11 dropped out within the first 5 months of the trial. This was probably due to lack of experience with the effect of this new slow-release formulation. Nine patients (82%) required an additional dose of standard Madopar, especially in the morning. Significant improvements were found for akinetic phenomenon and dystonic cramps, and with the global evaluation of motor fluctuations. The occurrence of peak dose dyskinesia remained unchanged. No abnormalities in laboratory values were found.
运动功能波动是帕金森病患者长期左旋多巴治疗中的一个主要问题。为减少这一问题，已研发出一种左旋多巴与苄丝肼的缓释制剂——美多芭HBS。22例晚期帕金森病且有明显运动波动的患者中，11例在使用美多芭HBS治疗后，运动功能波动得到持久改善；11例在试验的前5个月内退出，这可能是由于对这种新的缓释制剂效果缺乏经验所致。9例患者（82%）需要额外服用标准剂量的美多芭，尤其是在早晨。在运动不能现象、张力障碍性痉挛以及运动波动的整体评估方面有显著改善。峰值剂量异动症的发生率保持不变。未发现实验室值异常。
